The Future of Health Data Summit gathered leaders from across the healthcare ecosystem to discuss emerging opportunities and challenges around the use of health data to improve patient outcomes - including policy, regulatory, commercial, scientific, and technical perspectives.
Speaker: Senator Tom Daschle, Founder & CEO, The Daschle Group & Former Senate Majority Leader, Steve Swank, Chief Business Officer, Datavant
Moderated by Sam Roosz, Speaker: Janet Woodcock
Moderated by Jacob Plummer, Speaker: Robert Califf
Moderated by Vivek Ramaswamy, Speakers: Donna Cryer, Glen de Vries, Jamie MacDonald, Andrew Plump
Moderated by Sundeep Bhan, Speakers: Anne Heatherington, Jeremy Sohn, Ed Trautman, Lynn Vos
Moderated by Holly May, Speaker: Amy Abernethy
Moderated by Jules Polonetsky, Speakers: Inderpal Bhandari, Knut Mager, Kathryn Marchesini, Deven McGraw
Moderated by Richard Thomas, Speakers: Jay Bhatt, Aneesh Chopra, Scott Howe, Deborah Kilpatrick
Moderated by Charles Safran, Speakers: John Glaser, Kris Joshi, Donald Rucker, Anita Samarth
Moderated by Abel Kho, Speakers: Dan Brillman, Jeff Colyer, Lynnette Cooke, Stacy Lindau
Moderated by Jean Drouin, Speakers: Donald Berwick, Peter Levin, Suchi Saria, Russ Thomas
Moderated by Neal Katyal, Speakers: Andrew von Eschenbach, David Shulkin, Mona Siddiqui
Dan Brillman graduated from Yale University in 2006. He serves as a U.S. Air Force Pilot and Officer, graduating from Officer and Aviation Schools Command in 2008 before completing his MBA at Columbia University’s Business School in 2012. Dan was nominated for the Jefferson Award for Public Service in 2013.
Robert M. Califf, MD, MACC, is vice chancellor for health data science for the Duke University School of Medicine; director of Duke Forge, Duke’s center for health data science; and the Donald F. Fortin, MD, Professor of Cardiology. He is also an advisor for Verily Life Sciences. Dr. Califf served as Deputy Commissioner for Medical Products and Tobacco in the U.S. Food and Drug Administration (FDA) from 2015-2016, and as Commissioner of Food and Drugs from 2016-2017. A nationally and internationally recognized leader in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf is a graduate of Duke University School of Medicine. Dr. Califf was the founding director of the Duke Clinical Research Institute and is one of the most frequently cited authors in biomedical science.
Aneesh Chopra is the President of CareJourney, a Hunch Analytics company that provides actionable, clinically-relevant analytics services to population health organizations. He served as the first U.S. Chief Technology Officer under President Obama (’09-’12) and in 2014, authored, "Innovative State: How New Technologies can Transform Government.” He joined the Board of the Health Care Cost Institute in 2017, earned his MPP from Harvard Kennedy School and BA from The Johns Hopkins University.
Lynnette leads the global Health Division for Kantar, guiding the organization through organic and acquisition-related growth. Known as a great connector of people, she creates diverse teams to challenge each other and generate the best ideas for serving clients. Drawing on her consumer background and product management experience at Newell Rubbermaid, Lynnette brings fresh and innovative perspectives to the development of health specific offers and services with a distinct focus on the patient and real-world health outcomes. Under her leadership, the Health Division has transformed from being positioned solely as a marketing research company to also having a strong reputation in real-world evidence and value generation. Lynnette is chair of Kantar’s Corporate Responsibility programme, Extraordinary People, which includes a global partnership with Special Olympics. She is the executive sponsor to research that Kantar conducts for UN Women, to understand global attitudes and fulfill the sustainable development goal for Planet 50-50 by 2030. She serves on the Insights Association Board of Directors, is an assistant professor at Michigan State University and is also on their advisory board for their Master of Science in Marketing Research. In 2010, Lynnette was named one of the 100 Most Inspiring People in the life science industry by PharmaVOICE magazine and in 2011 she was the recipient of PMRG’s R.R. Fordyce Award.
Donna R. Cryer, JD, has channeled her personal experience as an IBD and liver transplant patient into professional advocacy as founder of CryerHealth, LLC consulting firm on patient-industry partnerships; the Global Liver Institute, a patient-driven advocacy non-profit operating in the US and Europe; and now as Interim Executive Director of the People-Centered Research Foundation, the Central Office for PCORnet. Mrs. Cryer serves on the Executive Committees for the Clinical Trials Transformation Initiative (CTTI) and the People-Centered Research Foundation, the Board of Trustees of Sibley Memorial Hospital/Johns Hopkins Medicine and the Executive Advisory Board for Tivity Health (NASDAQ: TVTY). Mrs. Cryer previous health data experience includes being appointed by the U.S. GAO to serve as the patient and consumer representative on the Health Information Technology Policy Committee, the federal advisory body to the National Coordinator for HIT, after serving on the Consumer Engagement and Privacy/Security Workgroups and as a member of Stakeholder Advisory Group to the NIH Learning Health System Research Collaboratory. She is a frequent speaker on patient engagement with health information technology at meetings of BIO, PhRMA, AHIP, National Quality Forum, mHealth Summit, Digital Health Summit, and the National Academies of Medicine. Mrs. Cryer received an undergraduate degree from Harvard/Radcliffe Colleges and a Juris Doctorate from the Georgetown University Law Center.
Senator Daschle is the Founder and CEO of The Daschle Group, A Public Policy Advisory of Baker Donelson. Senator Daschle served his home state, South Dakota, in the U.S. House of Representatives from 1979 until 1987 and in the U.S. Senate from 1987 to 2005. He is one of only two Senators to have served twice as both Majority and Minority Leader. In addition, Senator Daschle is Chair of the Board of Directors at the Center for American Progress, Vice-Chair for the National Democratic Institute and a co-founder of the Bipartisan Policy Center. He is the author of Like No Other Time: The 107th Congress and the Two Years That Changed America Forever; Critical: What We Can Do About the Health-Care Crisis; Getting It Done: How Obama and Congress Finally Broke the Stalemate to Make Way for Health Care Reform and U.S. Senate: Fundamentals of American Government. He has co-authored his most recent book, Crisis Point, with former Senator Trent Lott.
Jean Drouin, MD, is the founder and CEO of Clarify Health Solutions, which enables health systems, payers, and life sciences organizations to deliver more satisfying and efficient care through advanced analytics, machine learning, and digital care optimization solutions. Prior to Clarify, Jean was a Senior Partner at McKinsey & Company, where his roles included leading the global Healthcare IT and Digital Practice, setting up the UK and Australian Healthcare Practices, and serving as the founding Head of McKinsey Advanced Healthcare Analytics (MAHA). He also served as Head of Strategy for NHS London, which oversaw London’s $15B hospital and primary care system. In these roles, he served over 20 countries and 100 health systems and payers on engagements that generated over $1B in efficiency and quality improvements. Jean is passionate about transforming healthcare delivery across the continuum of care. He has written and spoken extensively on value-based care, population health, new payment models and the role of big data and analytics in delivering better outcomes. Jean holds MD and MBA degrees from Stanford and an AB in Molecular Biology from Princeton. He is the former Vice Chair of Lester B. Pearson United World College of the Pacific.
As senior advisor to Cerner Corporation, John Glaser is focused on strategic relationships with clients. John has devoted his career to advancing health care through innovation and helping clients maximize their investment in health care information technology. Prior to joining Cerner in 2015, John held senior executive leadership positions with Siemens Health Services, Partners HealthCare, and Brigham and Women's Hospital. John's accomplishments include founding chair of the College of Healthcare Information Management Executives (CHIME), past president of the Healthcare Information and Management Systems Society (HIMSS), the American College of Medical Informatics (AMIA), and former advisor to the Office of the National Coordinator for Health Information Technology (ONC). John received his Ph.D. from the University of Minnesota. He has written over 200 articles and three books on the strategic application of IT in health care, including the most widely used textbook on the topic, "Healthcare Information Systems: A Practical Approach for Health Care." John is on the faculty of the Wharton School at the University of Pennsylvania, the Medical University of South Carolina, the School of Biomedical Informatics at the Texas Health Science Center, and the Harvard School of Public Health.
Anne Heatherington Ph.D. has recently joined Takeda Pharmaceuticals as Senior Vice President and Head of Data Sciences Institute (DSI). In this role, she oversees many of the quantitative groups within Takeda, including Statistics and Quantitative Solutions, Global Health Outcomes and Epidemiology and Data Architecture and Digital Solutions. Her mandate is to drive innovation in R&D through focusing on knowledge infrastructure, enabling patient-centricity and developing tools and infrastructure to thoroughly understand the safety and efficacy of Takeda’s medicines. Anne has over 20 years’ experience leading organizations and programs in large pharma, mid-size biotechs and start-up organizations, including Summit Therapeutics, Pfizer Ltd and Amgen Inc. She has focused primarily on the application of quantitative principles to clinical drug development and decision-making. Anne received her bachelor’s degree in pharmacy from Queen’s University Belfast, Northern Ireland, and her Ph.D. in pharmacokinetics from the University of Manchester, England. She completed post-doctoral training in the Centre for Bioengineering at University of Washington, Seattle.
Scott Howe is the CEO of LiveRamp (NYSE: RAMP), a software-as-a-service (SaaS) company that provides the identity platform for powering exceptional experiences. LiveRamp is the largest provider of identity resolution services, serving more than 1,000 companies across a broad range of sectors including brands, agencies, technology vendors, data providers, and publishers. From 2011 to Sept. 2018, Howe served as CEO and president of LiveRamp’s former parent company, Acxiom—a technology and services company dedicated to providing the data foundation for the world’s best marketers. Before taking the reins at Acxiom in 2011, Howe held executive roles at Microsoft and aQuantive, where his teams built the world’s largest digital agency (Avenue A|Razorfish); pioneered people-based media buying (DRIVE Performance Media, aka the Microsoft Media Network); and developed the systems utilized for ad serving and attribution (Atlas International). Scott graduated magna cum laude from Princeton University with a degree in economics, and earned an MBA from Harvard University. He most recently served on the board of directors of Blue Nile, the largest online retailer of certified diamonds and fine jewelry, and is a former director of the Internet Advertising Bureau (IAB) and Turn, Inc., a digital advertising company.
Kris Joshi is executive vice president and president, Network Solutions, for Change Healthcare. Prior to joining Change Healthcare, Mr. Joshi was global vice president for healthcare product strategy for the Health Sciences global business unit at Oracle Corporation. He helped launch the Health Sciences business unit and successfully led two acquisitions for Oracle in Life Sciences. Before joining Oracle, Mr. Joshi served in senior strategy roles with IBM's Global Sales and Distribution organization, and prior to IBM, Mr. Joshi was at McKinsey and Company, where he worked with Fortune 500 companies on strategy issues. Mr. Joshi holds a B.S. in mathematics from the California Institute of Technology and a Ph.D. in physics from the Massachusetts Institute of Technology. He currently serves on the boards of the Personalized Medicine Coalition and the eHealth Initiative in Washington, DC
Neal Katyal is the Paul and Patricia Saunders Professor of Law at Georgetown University and a Partner at Hogan Lovells. He previously served as Acting Solicitor General of the United States. He has argued 39 cases before the Supreme Court of the United States, with 37 of them in the last decade. Most recently, Neal argued the "Travel ban" case on behalf of the State of Hawaii against President Trump in the Supreme Court of the United States. In the 2016-17 term alone, Neal argued 7 cases in 6 separate arguments at the Supreme Court, far more than any other advocate in the nation - nearly 10% of the docket. At the age of 49, he has already argued more Supreme Court cases in U.S. history than has any minority attorney, recently breaking the record held by Thurgood Marshall. His numerous distinctions include: the Edmund Randolph Award (the highest civilian award given by U.S. Department of Justice), The Litigator of the Year by American Lawyer (2017 and 2018, chosen as the sole Grand Prize Winner of all the lawyers in the United States), Appellate MVP by Law360 numerous times (most recently in 2017), winner of Financial Times Innovative Lawyer Award in two different categories (both private and public law) (2017), one of GQ's Men of the Year (2017), 40 Most Influential Lawyers of the Last Decade Nationwide by National Law Journal (2010), and 90 Greatest Washington Lawyers Over the Last 30 Years by Legal Times (2008). He has appeared on virtually every major American news program, as well as on Stephen Colbert and House of Cards on Netflix (where he played himself).
Abel Kho received his MD from the Medical College of Wisconsin and completed a residency and Chief residency in Internal Medicine at the University of Wisconsin, Madison. He completed a NLM/NIH fellowship in Medical Informatics at the Regenstrief Institute before joining the faculty at Northwestern University. Abel is Associate Professor of Medicine and Preventive Medicine in the Feinberg School of Medicine at Northwestern University and Director of the Center for Health Information Partnerships (CHiP www.healthinformationforall.org). He has served as PI for several regional or national projects including the ONC funded Chicago Health IT Regional Extension Center (www.chitrec.org), the PCORI funded Chicago Area Patient Centered Outcomes Research Network (http://capricorncdrn.org/), and the AHRQ funded Health Hearts in the Heartland consortium (http://www.healthyheartsintheheartland.org/) within the EvidenceNOW initiative. His research focuses on developing regional Electronic Health Record (EHR) enabled data sharing platforms for a range of health applications including high throughput phenotyping, cohort discovery, estimating population level disease burden, and quality improvement.
Deb Kilpatrick is the Chief Executive Officer of Evidation Health. She is a Director for both the Task Force for Global Health and Sleep Number (NASDAQ: SNBR), serves on the Georgia Tech and Cal Poly Engineering Advisory Boards, and is a Fellow of the American Institute of Medical and Biological Engineering. Earlier in her career, Deborah held leadership roles at CardioDx and Guidant Corporation, where she was Research Fellow, Director of R&D, and Director of New Ventures in its Vascular Intervention Division prior to its acquisition by Boston Scientific. Deborah is a co-founder of the MedtechVision Conference, now held annually in Silicon Valley. She holds BS, MS and PhD degrees in mechanical engineering with a bioengineering focus from Georgia Tech.
Peter L. Levin is the CEO of Amida Technology Solutions, an open source software company that focuses on data management and data security. Peter is also an adjunct senior fellow at the Center for a New American Security, an independent director of Conversa Health, and a Strategic Advisor to Government Executives (SAGE) with the Partnership for Public Service. Immediately prior to co-founding Amida, he was Senior Advisor to the Secretary and Chief Technology Officer of the Department of Veterans Affairs, where he led their health record modernization initiative. His background is in applied math and high performance computing. He has published nearly a hundred articles on modeling and simulations, cybersecurity, satellite navigation, semiconductor design, and technology policy in peer-reviewed journals as well as distinguished outlets in the popular press. Peter was a director of the network security company Astaro (acquired by Sophos), and co-founder of the GPS-based cybersecurity company Zanio (acquired by Boeing). He was a White House Fellow in the Office of Management and Budget, a Humboldt Fellow in the Department Mathematical Physics at the Technical University of Darmstadt, an NSF Presidential (Bush '41) Young Investigator, a DAAD Visiting Scientist at the University of Munich, and a winner of an NIST Advanced Technology Program award.
Stacy Tessler Lindau, MD, MAPP, tenured Professor of Ob/Gyn and Medicine-Geriatrics at the University of Chicago, is a population health scientist, a community-engaged researcher and a practicing physician. She is PI of the program of research for CommunityRx, a large scale but low-intensity clinic-to-community linkage intervention, developed and tested with support from a Round I Health Care Innovation Award from the US Center for Medicare and Medicaid Innovation (CMMI), NIH and AHRQ. The CMMI funding had, as an expectation, that awardees implement a sustainable business model. To deliver on this commitment, she founded NowPow, LLC and MAPSCorps, 501c3, both headquartered on the South Side of Chicago where CommunityRx was developed. Dr. Lindau is also a practicing gynecologist and expert on sexuality in the context of aging and illness. She is director of the Program in Integrative Sexual Medicine at the University of Chicago and founding Chair of the Scientific Network on Female Sexual Health and Cancer. Dr. Lindau is a graduate of the University of Michigan Honors College, Brown University School of Medicine, the University of Chicago Harris School of Public Policy Studies and was Chief Administrative Resident in Ob/Gyn at Northwestern University’s McGaw Medical Center. She was a Robert Wood Johnson Foundation Clinical Scholar and served its National Advisory Committee. She was an Aspen Institute Health Innovator Fellow and serves its Board of Overseers. She is president of MAPSCorps and serves the board of directors of RISE, an organization devoted to the elimination of racism through sport.
Jamie Macdonald is Chief Executive Officer of Parexel. He has nearly 25 years of experience in leading global biopharmaceutical services companies. Prior to joining Parexel, Mr. Macdonald served as CEO of INC Research, now known as Syneos Health, from January 2013 through September 2016, where he led the company through a successful Initial Public Offering in 2014. Mr. Macdonald also served as INC’s Chief Operating Officer from July 2011 through December 2012, and previously held several leadership positions in the biopharmaceutical services industry, including Senior Vice President and Head of Global Project Management at Quintiles, now known as IQVIA. Prior to this, he held various senior operational and finance roles at Quintiles. He currently serves on the Board of Directors for the Association of Clinical Research Organizations (ACRO), having previously served as its Chairman in 2015. Mr. Macdonald’s recent experience also includes serving as Chairman of the Board for Certara, a drug development consultancy with solutions spanning discovery, preclinical and clinical drug development, from 2017 to 2018. Mr. Macdonald began his career in the pharmaceutical industry with Syntex Corporation (acquired by Roche Holdings, Inc.). A native of Scotland, he holds a B.A. in Economics from Heriot-Watt University in Edinburgh, Scotland and is a qualified Chartered Management Accountant (ACMA).
Knut joined Novartis in 2003 as General Counsel, Head of Legal of the Sandoz Division. Since 2007, Knut Held various leadership positions within Novartis Group Legal inter alia Head of Commercial Legal and Head Country Legal Organizations. He started his career in 1990 at Schering AG (now Bayern) in Berlin, Germany where he held various positions inter alia Head of Patents and Head of Corporate Strategy.
Deven McGraw is general counsel and chief regulatory officer for Ciitizen, a consumer health technology start-up. Previously she directed U.S. health privacy and security as deputy director of health information privacy at the HHS Office for Civil Rights and chief privacy officer (acting) of the Office of the National Coordinator for Health IT. Widely recognized for her expertise in health privacy, she directed the Health Privacy Project at the Center for Democracy & Technology for six years and led the privacy and security policy work for the HITECH Health IT Policy Committee. She also served as the COO of the National Partnership for Women and Families. She advised health industry clients on HIPAA compliance and data governance while a partner at Manatt, Phelps & Phillips, LLP. Deven graduated from Georgetown University Law Center and has a masters of public health from Johns Hopkins University.
Andrew Plump, M.D., Ph.D., is the President, R&D at Takeda Pharmaceutical and serves as a member of the company’s Board of Directors. His career spans nearly 30 years in the pharmaceutical industry and academia and his experience encompasses early research through regulatory approval and patient access. Dr. Plump’s approach toward drug research and development is reflected in a virtuous cycle of “bench to bedside to bench” learning. He is a true translational physician-scientist, with deep knowledge in biomedical research, experimental medicine, early development, genomics and biomarkers and a history of scientific contributions in neuroscience, cardiovascular and metabolic diseases Throughout his career, Dr. Plump has been motivated to make an impact for patients by translating groundbreaking science into the practice of healthcare. He is regarded as a multi-dimensional leader who is passionate about leading diverse, cross-functional teams and nurturing a high-performing culture to achieve a shared mission, innovate for patients and change health for the better. Currently, Dr. Plump leads a modern, world-class R&D organization focused on three therapeutic areas: gastroenterology, neuroscience and oncology, plus vaccines. Through the application of novel modalities and a rich partner ecosystem, the Takeda R&D organization is committed to delivering innovative solutions that address unmet needs. Prior to Takeda, Dr. Plump served as Senior Vice President, Research & Translational Medicine, Deputy to the President of R&D at Sanofi, based in Paris, France. Prior to Sanofi, Dr. Plump served as Vice President, Worldwide Cardiovascular (CV) Research Head at Merck, where he had direct responsibility for CV research, preclinical development and translational sciences. Dr. Plump received his M.D. from the University of California, San Francisco (UCSF), his Ph.D. in cardiovascular genetics with Dr. Jan Breslow at Rockefeller University and his B.S. from the Massachusetts Institute of Technology (MIT). He completed a residency in Internal Medicine and a fellowship in Medical Genetics at UCSF. Following his clinical training, Dr. Plump trained as a Howard Hughes and Stanley J. Sarnoff postdoctoral fellow with Dr. Marc Tessier-Lavigne at UCSF, concurrently assuming faculty responsibilities as an Adjunct Clinical Instructor in the Department of Medical Genetics.
Jules Polonetsky serves as CEO of the Future of Privacy Forum, a Washington, D.C.-based non-profit organization that serves as a catalyst for privacy leadership and scholarship, advancing principled data practices in support of emerging technologies. FPF is supported by the chief privacy officers of more than 150 leading companies, several foundations including the US National Science Foundation, as well as by an advisory board comprised of the country’s leading academics and advocates. FPF’s current projects focus on AI, Adtech, Ethics and Data Driven Research, Health, Smart City, Connected Cars and Student Privacy.
Vivek Ramaswamy is the Founder and Chief Executive Officer of Roivant Sciences, a healthcare company focused on unlocking innovation in medicine. Roivant builds and operates “Vants” – nimble, entrepreneurial biotech and health technology companies with a unique approach to sourcing talent, aligning economic incentives, and deploying technology to drive greater efficiency in R&D. Roivant has over 800 employees and over 35 investigational medicines in development across its family of companies and has raised over $3 billion in capital to support its mission. Prior to founding Roivant in 2014, Mr. Ramaswamy was a successful investor in the biotechnology sector where he oversaw investment in a curative treatment regimen for hepatitis C virus. He received his A.B. summa cum laude in Biology from Harvard College and his J.D. from Yale Law School, where he was a Paul & Daisy Soros Fellow.
Dr. Don Rucker is the National Coordinator for Health Information Technology @ U.S. Department of Health & Human Services, where he leads the formulation of the federal health IT Strategy & coordinates federal health IT policies, standards, programs, & investments.
Anita Samarth is the CEO and Co-founder of Clinovations Government + Health, a management consulting firm focused at the intersection of health, technology, and policy. Anita has over 25 years of experience in health care technology and worked on health IT initiatives at over 200 provider organizations nationwide. Over the last 15 years, Anita has focused on bridging the gap between commercial health care and government initiatives by leading health IT interoperability initiatives funded by AHRQ, DoD/VA, HHS, ONC, and NIST. The Washington Business Journal recently honored Ms. Samarth as a 2013 Minority Business Leader and 2013 Women Who Mean Business. She is the author of Interoperability for Dummies and co-author of EHRs for Dummies from Wiley Publishing. She currently serves on the Board of Trustees for the American Board of Internal Medicine Foundation, providing insight on the use of EHRs and health IT on medical professionalism. She is a member of the Board of Directors for Costs of Care, a non-profit that educates, advocates, and supports improving the value and affordability of healthcare. She is also the co-founder of Clinovations, a healthcare management consulting firm which was acquired by the Advisory Board Company/Optum.
Suchi Saria is an internationally renowned leader in AI and health. Most recently she was named to World Economic Forum’s Young Global Leaders, Popular Science’s “Brilliant 10”, Technology Review’s “35 Innovators under 35” and National Academy of Medicine’s Emerging Leaders in Health and Medicine. She holds a John C. Malone endowed chair at Johns Hopkins where she leads the one of the top labs nationally in AI, machine learning, and Health. She is also part of several efforts by the National Academies on learning and health. She is on the advisory board of Scripps Translational Research, Novartis Cardiology Data Science, Patient Ping, and is the founder of Bayesian Health. Bayesian is powering health system transformation into the digital data era by empowering providers and health systems with real-time access to inferences to make care safer and more efficient.
Dr. Siddiqui is the Chief Data Officer for the US Department of Health and Human Services where she is driving the strategy to connect the nation’s healthcare data. As she leads the effort to build and implement the first HHS enterprise wide data sharing platform and governance structure, she is also responsible for advancing the Department’s AI strategy. Prior to this role, Dr. Siddiqui was at the Centers for Medicare and Medicaid Innovation advancing rapid cycle testing for technology enabled care models. She has also led work for the health portfolio for the White House Social and Behavioral Sciences Team (“nudge” unit) during the Obama administration. She has a MD from the Johns Hopkins School of Medicine, a masters in quantitative methods from the Harvard School of Public Health and management/engineering from the Stanford School of Engineering.
Jeremy joined Novartis in 2015 as VP, Head of Digital Business Development & Licensing reporting to our Chief Digital Officer and supporting Novartis' digital innovation programs cross-divisionally and globally. While serving in this role, Jeremy was also appointed ad-interim Global Head of Commercial Digital Medicines (2017), overseeing the digital medicine leads within the global franchises and regions, and, Global Head of Digital Development (2016), leading Novartis' clinical trial innovation efforts within Global Drug Development. Jeremy is a seral software entrepreneur with more than 20 years of experience founding and managing healthcare and technology companies. Jeremy is a Board Member and Advisor to a number of digital health companies, including Pear Therapeutics, Science 37, MintHealth, Neural Analytics, and COTA. Prior to Novartis, Jeremy was Managing Director at MPM Capital where he led the firm's digital-health investment strategy. At MPM, Jeremy founded tow companies, CentrosHealth (acquired by Clinical Ink) and TriNetxX. In 2011, Jeremy co-founded GrapeVine, a software company that optimizes how organizations connect with their target communities. From 2007-2011, Jeremy was COO and VP, Strategy & Corporate Development for North Plains Systems, where he lead the company's growth and eventual sale to Accel-KKR. In 2000, he co-founded an open-source operating system company, Wasabi Systems.
Charles Safran is a primary care physician who has helped transform healthcare through the creative use of communication and information technologies. In 2014 he was awarded the Morris F. Collen Award, the highest honor given by the American College of Medical Informatics given to an individual whose personal commitment and dedication to biomedical informatics has made a lasting impression on healthcare and biomedicine. As a Professor of Medicine at Harvard Medical School and former Chief of the Division of Clinical Informatics at Beth Israel Deaconess Medical Center, Dr. Safran has helped develop and deploy large institutional clinical computing systems, electronic health records, clinical decision support system to help patients with HIV/AIDS, telehealth systems to support parents with premature infants, and most recently eHealth solutions for families with fail elders. He was the President and Chairman of the American Medical Informatics Association and Vice-President of the International Medical Informatics Association. He is an elected fellow of both the American College of Physicians and the American College of Medical Informatics. He is Director of Intelligent Medical Objects; a terminology company that helps clinicians capture clinical intent as well as a scientific advisor to Datavant. Dr. Safran is a widely sought speaker on the future of healthcare technology, has testified for the U.S. Congress and has over 200 publications. He graduated cum laude in Mathematics and hold a masters degree in Mathematical Logic and a Doctor of Medicine all from Tufts University and an honorary Masters in Arts from Harvard University.
David Shulkin, MD, a national thought leader on veterans’ health and patient-centered care, was appointed by President Donald Trump as the 9th United States Secretary of Veterans Affairs, and served in the role from February 2017 until March 2018. He also served as the Under Secretary of Veterans Affairs for Health under President Barack Obama from 2015-2017. The Department of Veterans Affairs is the second largest federal government agency, and the Secretary oversees the National Cemetery Administration, the Veterans Benefits Administration, and the Veterans Health Administration. Under Secretary Shulkin’s leadership, the Department streamlined the appeals process for veterans seeking disability benefits, made wait times more transparent, and improved mental health services. Before his time in government, Dr. Shulkin had a long career of health care leadership and management, including at the University of Pennsylvania Health System (now Penn Medicine), as well as Temple University Hospital, Beth Israel Medical Center, and the Morristown Medical Center. He was also a Robert Wood Johnson Foundation Clinical Scholar at Penn, is currently the Distinguished Health zoology Fellow at the University of Pennsylvania Leonard Davis Instiute of Health Economics (LDI). “Penn LDI provides a unique forum in which to continue my work on important policy issues that can impact the lives of veterans and all Americans. Coming back to Penn in this way is very exciting,” says Dr. Shulkin.
Russ Thomas is the Chief Executive Officer of Availity. His vision helped to diversify Availity’s solutions and grow its customer base, creating the foundation for the expansive Availity network that exists today. Combined, the enterprise now delivers healthcare business solutions to a growing network that connects more than 1,000,000 physicians and allied care providers, 2,700 hospitals, and more than 600 technology partners with health plans nationwide. Under Thomas’s leadership, Availity is leading the charge in provider engagement and empowering health care professionals to improve results. Before joining Availity, Thomas was CEO of Gold Standard, a drug information database and clinical knowledge solution. Thomas grew the company from a small start-up to a multi-sector leader in the healthcare market before selling the business to Reed Elsevier in 2006. He remained with Reed Elsevier as a senior executive in their clinical information business until 2008. Thomas is active in many industry and philanthropic organizations. He serves on the Board of Directors for eHealth Initiative, a Washington, D.C. based non-profit organization that seeks to drive improvements in the quality, safety, and efficiency of healthcare through information technology. In 2015, he served as Chair of the United Way Northeast Florida Annual Campaign. Through the United Way, Availity developed a partnership with Ribault Middle School in the “Achievers for Life” dropout prevention program. He is a member of the Board of Trustees for Jacksonville University. A licensed commercial pilot, Thomas was appointed to the Jacksonville Aviation Authority board of directors in 2015. Thomas earned his Bachelor of Arts degree from Virginia Tech and his Juris Doctorate from the University of Virginia. He lives in Ponte Vedra, Florida with his wife Claudia and their two children. He is an avid cyclist.
Ed Trautman, Ph.D., Vice President Science and Clinical Analytics and Informatics at Pfizer, has been involved with healthcare and technology for over three decades, serving on the staff at Massachusetts General Hospital and on the faculties of Harvard Medical School and MIT before growing several small businesses and leading healthcare technology groups. Ed led development of the first commercial electronic medical record system at Cerner, of Internet-based pharmacy benefit management at CareInsite (now WebMD), and extended Harvard's evidence-based risk management and patient safety tools and services to many national healthcare systems as president of RMF Strategies. More recently Ed was COO and led development of next generation DNA diagnostics and reporting at Correlagen prior to its acquisition by LabCorp in 2009 to seed its advanced genomics testing services and build clinical reporting. Dr Trautman is currently part of Pfizer's new Digital Technology team that is driving digital transformation across the full spectrum of product research, development , manufacturing, commercialization and customer experiences. Dr Trautman received his B.S., M.S., and Ph.D. in electrical engineering and computer science (biomedical engineering) from MIT.
Janet Woodcock is Director of the Center for Drug Evaluation and Research (CDER), at the Food and Drug Administration (FDA). In 2015, Dr. Woodcock also assumed the role of Acting Director of CDER’s newly formed Office of Pharmaceutical Quality, (OPQ). Dr. Woodcock first joined CDER in 1994. For three years, from 2005 until 2008, she served FDA’s Commissioner, holding several positions, including as Deputy Commissioner and Chief Medical Officer, Deputy Commissioner for Operations, and Chief Operating Officer. Her responsibilities involved oversight of various aspects of scientific and medical regulatory operations. Before joining CDER, Dr. Woodcock served as Director, Office of Therapeutics Research and Review, and Acting Deputy Director in FDA’s Center for Biologics Evaluation and Research. Dr. Woodcock received her M.D. from Northwestern Medical School and completed further training and held teaching appointments at the Pennsylvania State University and the University of California in San Francisco. She joined FDA in 1986.
Andrew C. von Eschenbach, M.D. currently serves as President of Samaritan Health Initiatives. In September of 2005, he assumed leadership of the Food and Drug Administration where he immediately engaged an agenda to modernize the FDA. Confirmed by the Senate as Commissioner in December 2006, he emphasized innovation by fostering creative projects, including FDA’s Critical Path Initiative and the FDA’s Food Protection Plan; and an Agency-wide fellowship program and development of a new integrated campus for the Agency in White Oak, Maryland. In addition to expanding FDA’s international role by establishing FDA offices around the world, he internally fostered, through process improvements, a regulatory pathway that is transparent and efficient while still rigorous and science led. Dr. von Eschenbach joined FDA after serving for four years as Director of the National Cancer Institute (NCI) at the National Institutes of Health. At the time of his appointment by President Bush to serve as Director of NCI, he was President-Elect of the American Cancer Society. Dr. von Eschenbach entered government service after an outstanding career over three decades as a physician, surgeon, oncologist and executive that included numerous leadership roles from Chairman of the Department of Urologic Oncology to Executive Vice President and Chief Academic at the University of Texas M.D. Anderson Cancer Center in Houston. He is the author of more than 300 scientific articles. He has received numerous professional awards and honors. In 2006, Dr. von Eschenbach was named one of Time magazine’s “100 most influential people to shape the world,” and in both 2007 and 2008, he was selected as one of the Modern Healthcare/Modern Physician’s “50 Most Powerful Physician Executives in Healthcare.” Dr. von Eschenbach earned a B.S. from St. Joseph’s University in his native Philadelphia and his medical degree from Georgetown University School of Medicine in Washington, D.C. He served as a Lt. Commander in the U.S. Navy Medical Corps. After completing a residency in urologic surgery at Pennsylvania Hospital in Philadelphia, he was an instructor in urology at the University of Pennsylvania School of Medicine. He completed a Fellowship in Urologic Oncology at the University of Texas M.D. Anderson Cancer Center.
Lynn is the President and CEO of the Muscular Dystrophy Association (MDA), dedicated to transforming the lives of people with neuromuscular disease through innovations in science and innovations in care. Lynn has a hands-on appreciation for patient care, and she has considerable executive experience and expertise in the fields of pharmacology, medical and clinical education, technology, and digital marketing. Prior to her arrival at MDA, Lynn was the CEO of ghg | greyhealth group for nearly 23 years and is credited with creating, building and acquiring companies — specifically, nine acquisitions — to grow ghg’s global footprint. While at ghg, Vos led global expansion and diversification strategies and within two years grew the company from a small, domestic professional player into an award-winning global enterprise with fully integrated, multi-channel offerings. She is a recognized thought leader in the industry with published white papers and articles outlining new, successful approaches to health care technology and communication. Lynn has public and private board experience, including OptimizeRx (OTC: OPRX), the Jed Foundation, a leading mental health nonprofit, and the Multiple Myeloma Research Foundation (MMRF). She was named Woman of the Year by the Healthcare Businesswomen’s Association in 2005.
Glen is the President and Co-founder of Medidata Solutions, the leading cloud platform for life sciences research. Glen has been driving Medidata's mission since the company’s inception in 1999: Powering smarter treatments and healthier people. His publications have appeared in Applied Clinical Trials, Cancer, The Journal of Urology, Molecular Diagnostics, STAT, Urologic Clinics of North America and TechCrunch. He is a trustee of Carnegie Mellon University, a Columbia HITLAB Fellow, and a member of the Healthcare Businesswomen’s Association European Advisory Board. Glen received his undergraduate degree in molecular biology and genetics from Carnegie Mellon University, worked as a research scientist at the Columbia Presbyterian Medical Center and studied computer science at New York University's Courant Institute of Mathematics. You can follow Glen on Twitter at @CaptainClinical.
Steve Swank is the Chief Business Officer of Datavant. Mr. Swank has held numerous sales leadership positions at technology and enterprise sales companies. Most recently, he served as Chief Revenue Officer at RPX Corporation (NASDAQ:RPXC) where he grew the client base by over 300 clients and more than quintupled revenue to $330 million in December of 2017. Prior to RPX, he served as the Vice President of Sales at Comdata. Mr. Swank received his BA in Economics from Bucknell University and his MBA from The University of Chicago Booth School of Business.
Sam is a co-founder and General Manager of Life Sciences at Datavant. He is healthcare product veteran with experience in pharma, biotech, and diagnostic companies to bring over 15 products to market. Sam received a degree in Molecular and Cellular Biology from Harvard, and holds an MBA from the Stanford Graduate School of Business. Glen received his undergraduate degree in molecular biology and genetics from Carnegie Mellon University, worked as a research scientist at the Columbia Presbyterian Medical Center and studied computer science at New York University's Courant Institute of Mathematics.
Jake Plummer is General Manager of Health Systems & Government at Datavant. Previously Jake was CEO of Health Data Link - now a part of Datavant. He has been involved in the health sector for over fifteen years and began his healthcare career as a hospital executive at University of Chicago Medical Center. He has led strategy, corporate business development, sales, and go-to-market activities for companies in the Electronic Medical Record, Population Health, and Telemedicine sectors, both within and outside the United States. Jake has a MPP in Health Policy and an MBA, both from the University of Chicago.
Holly May is Head of People and Operations at Datavant. Prior to Datavant, Holly led business operations at Elementum, a SaaS platform for supply chain management. Previously, she supported the commercialization of dozens of medical innovations across pharma, biotech, devices, and tech-enabled medical services. Holly received a degree in History of Science from Harvard and holds a MBA from Stanford Graduate School of Business.